Sedana Medical Q3 Sales Rise 7% at Constant FX; FDA Accepts NDA
Q3 net sales were SEK 44.2 million, up 7% at constant FX. The FDA accepted the NDA and set an April 16, 2027 PDUFA date. Year-to-date EBITDA improved to negative SEK 7.1 million from negative SEK 10.2 million; cash was SEK 40 million with SEK 50 million in credit available.